Tandem Diabetes Care (TNDM) stock experienced a significant pre-market plunge of 16.61% on Thursday, following the release of the company's fourth-quarter and full-year 2024 financial results that missed analysts' expectations.
The medical device maker reported an adjusted operating loss of $30.2 million for Q4, wider than analysts' estimate of a $17.6 million loss. Additionally, the adjusted net loss for the quarter came in at $28.8 million, missing the consensus estimate of a $14.9 million loss. The disappointing results were primarily driven by weaker-than-expected sales and higher costs.
Looking ahead, Tandem Diabetes Care provided a gloomy outlook for the current year, further weighing on investor sentiment. The company expects an adjusted net loss of $1.20 per share on revenue of $1.01 billion for 2025, falling short of analysts' projections.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。